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Abstract: This study aims at developing a completely new class of 
MRI contrast agents, displaying remarkable relaxation effects in the 
absence of paramagnetic metal ions. Their detection requires the 
acquisition of images at variable magnetic field strength as provided 
by Fast Field Cycling imaging scanners. They contain poly-histidine 
chains (poly-His), whose imidazole groups generate 14N-Quadrupolar-
Peaks that cause a relaxation enhancement of water protons at a 
frequency (1.38±0.3 MHz) that is readily detectable from the 
frequencies associated with endogenous proteins. The poly-His QPs 
are detectable only when the polymer is in a solid-like form, i.e. at pH 
> 6.6. Above this value, their intensity is pH dependent and can be 
used to report on the occurring pH changes. On this basis, the poly-
His moieties were conjugated to biocompatible polymers such as 
polylactic and glycolic acid, in order to form stable nanoparticles able 
to encapsulate structured water in their core. FFC images were 
acquired to assess their contrast-generating ability.  
Introduction 
 In the last few decades, Magnetic Resonance Imaging (MRI) has 
become one of the key modalities in clinical settings thanks to its 
superb spatial resolution and its outstanding ability to differentiate 
soft tissues. The contrast in an MR image arises mainly from 
differences in the relaxation times (T1 and T2) of tissue water 
protons, as a consequence of their interaction with 
macromolecules, paramagnetic metal ions and biological 
membranes. On this basis, it was rather straightforward in the 
1980s to seek MRI contrast agents in the field of paramagnetic 
systems, whose ability to shorten the water proton relaxation rates 
was already well established [1]. The Gd(III) ion with its seven 
unpaired electrons and its (relatively) long electronic relaxation 
time was quickly identified as the candidate of choice for this 
application. As free Gd(III) ions are toxic for biological systems, it 
was suggested to use Gd-containing complexes with octadentate 
ligands that wrap around the metal ion leaving one coordination 
site available for the coordination of a water molecule in fast 
exchange with “bulk” water [2,3]. Thus Gd-Based Contrast Agents 
(GBCAs) yield an increase of water proton relaxation rates in the 
regions where they distribute. Currently, about 40% of the MRI 
scans carried out in clinical settings make use of GBCAs [4]. They 
are quickly excreted from the patients’ bodies after i.v. 
administration at doses of 0.1-0.3 mmol/kg with a t1/2 of the order 
of one hour. In recent years, it has been shown that tiny amounts 
of Gd may be retained in the tissues of patients injected with 
GBCAs [5]. Although clinical consequences have been reported 
only in the case of patients with impaired renal function, these 
observations bring a growing concern about the use of GBCAs [6–
8]. Thus, probe developers are urgently challenged to find 
alternatives to GBCAs [9–11]; the problems raised by GBCAs 
suggest addressing routes that do not involve metal complexes. 
Meanwhile, researchers’ attention is also devoted to the search 
for innovative solutions that could allow in vivo applications that 
would not have been possible using GBCAs.  
In the search for alternatives to GBCAs (and related paramagnetic 
complexes based on Mn(II), Mn(III) or Fe(III)) we were inspired by 
the relaxation enhancement brought about by “semi-solid” 
proteins in biological tissues [12,13]. In fact, “relaxation 
enhancement peaks” at specific values of applied magnetic field 
were reported early in the NMR study of immobilized proteins [14,15], 
as well in the case of biological tissues. The occurrence of these 
peaks is readily detectable at defined frequencies in the Nuclear 
Magnetic Relaxation Dispersion (NMRD) curve of the investigated 
specimen [16–18], and were associated with the amide 
functionalities of immobilized (semi-solid) proteins as the 
relaxation enhancement occurs at the magnetic fields where the 
proton NMR frequency coincides with the frequency of the 14N 
nuclear quadrupole resonance (NQR) of the amide groups. These 
relaxation enhancement peaks were therefore deemed “14N 
quadrupolar peaks” (14N-QPs, Figure 1). We surmised that other 
14N containing functionalities may be the source for proton 
relaxation enhancements at frequencies different from those 
reported for the protein amide groups. This approach may lead to 
a novel class of “frequency-encoding” agents that eventually may 
prompt the development of MRI scanners operating at magnetic 
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employed for in vivo studies. Ideally, the frequency-encoding 
agents would be the best candidates for Fast Field-Cycling (FFC) 
imaging scanners [19,20] as the subtraction of images acquired at 
different magnetic fields may allow one to fully exploit the potential 
associated with the field-dependence of proton relaxation rates. 
An additional difference with GBCAs arises from the need to work 
with immobilized systems, as 14N-QPs disappear completely 
when the agent is in the solution state [18]. Therefore, one has to 
envisage moieties that act as contrast agents when they are 
under the form of particles or even as components of implant 
devices such as scaffolds for regenerative medicine applications.  
Herein we report our observations on imidazole-containing 
peptides that appear to be excellent representatives of this novel 
class of MRI 14N-QP-based contrast agents.  
 
Figure 1. NMRD profile of immobilized protein. (A) NMRD profile of cross-
linked Bovine Serum Albumin (BSA) with a multi-exponential decay to 
background dispersion, excluding data in the QP ranges. In the inset, the energy 
levels of 14N nuclei (S ≥ 1) due to QP interactions with local electric field 
gradients are reported. The two levels to the left occur for axial symmetry. The 
upper level splits when the axial symmetry is broken, as shown to the right. A 
local maximum of the R1 profile of protons occurs when the Zeeman transition 
energy of the proton spin is equal to the energy difference of two levels of the S 
spin. (B) Lorenzian fits to the QPs.  
 
In the case of biological tissues, the 14N-QPs are detected at the 
proton NMR frequencies of 0.7, 2.1 and 2.8 MHz, equivalent to 
field strengths of 16 mT, 49 mT and 65 mT [18]. For such systems, 
it is well established that the detection of the QPs is associated 
with the presence of endogenous amidic peptide groups. 
Furthermore, it was shown that the amplitude of the 14N-QPs  is 
proportional to the amount of protein present in the considered 
specimen [21]. This observation prompted investigations aimed at 
showing that the detection of 14N-QPs may act as a reporter of an 
ongoing pathology that affects the amount and mobility of the 
associated proteins. The present work shows how it is possible to 
develop an innovative class of MRI contrast agents based on the 
generation of detectable 14N-QPs that fall at frequencies well-
distinct from those generated from the amidic peptide 
functionalities of the endogenous proteins. Thus, the QPs arising 
from the exogenous contrast agent can be easily identified and 
their detection will not be affected by the presence of endogenous 
QPs.  
Results  
The proof-of-concept of generating 14N-QPs different from those 
due to the tissues’ immobilised proteins was achieved by using 
an aqueous suspension of particles of poly-histidine polymer. 
Unlike all the immobilized proteins or specimens of biological 
tissues reported to date in the literature, the NMRD of poly-
Histidine (poly-His, Figure 2A) showed a characteristic relaxation 
peak at 1.38 MHz due to the 14N nuclear quadrupole resonance 
frequency of the imidazole groups present on the polymeric chain 
[22]. Two additional 14N-QPs from the imidazole group appear as 
broad peaks at about 0.98 and 0.7 MHz, respectively, but they are 
not useful for the intended application because of the overlap with 
the 14N-QPs at 0.7 MHz arising from the tissue protein amidic 
groups. Figure 2B reports the NMRD profile of poly-His (MW= 
15,600, dispersed in water at 30%w/w), showing the characteristic 
14N-QPs that are compared with the NMRD profile of an ex vivo 
fresh muscle tissue from a BALB/c mouse.  
The 14N-QP at 1.38±0.5 MHz arising from the imidazole groups is 
readily detectable and distinct from the QPs generated by the 
background tissue (figure 2C and 2D).  
The increase of water proton relaxation rate (R1) and the 
relaxation enhancement were calculated using the following 
equations: 
 
∆𝑅1  =  𝑅1
1.38𝑀𝐻𝑧 − 𝑅1
1.65𝑀𝐻𝑧 (s-1)     Equation 1 
 
𝑟𝑒𝑙𝑎𝑥𝑎𝑡𝑖𝑜𝑛 𝑒𝑛ℎ𝑎𝑛𝑐𝑒𝑚𝑒𝑛𝑡 = ∆𝑅1 𝑅1
1.65𝑀𝐻𝑧⁄ ∗ 100       Equation 2 
 
Where the relaxation rate at 1.38 MHz and 1.65 MHz correspond 
to the top and the base values of the imidazole peak of poly-His, 
respectively. 
The relaxivity enhancement of poly-His was ca. 70% 
corresponding to a R1  6 s-1. 
NMRD profiles acquired on specimens at different poly-His 
concentrations are reported as Supplementary Materials (Figure 
S1). Although the 14N-QP at 1.38 MHz still remained detectable at 
the lowest tested concentration (5 mg/ml), we suggest that the 14 
mg/ml concentration, corresponding to a relaxation enhancement 
of 49% and a R1 of 0.4 s-1, should represent a reasonable 
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Figure 2. The poly-His. (A) Schematic representation of poly-His. (B) NMRD 
profile acquired from 0.01 to 20 MHz of poly-His (30% w/w) in water (●) 
compared with the NMRD profile of an ex vivo fresh muscle tissue (○) from 
BALB/c mouse (T=25°C). A multi exponential decay fitting to background 
dispersion, excluding data in the QP ranges, was performed for poly-His (black 
line). The asterisk * identifies the imidazole peak in the side-chain of poly-His. 
Expansion of the QPs region before (C) and after (D) the background 
subtraction with Lorenzian fits to the QPs. (E) The R1 of the 14N-QP peak 
(equation 1) as a function of the pH, for a 15 mg/ml poly-His sample. The line is 
to guide the eyes. 
 
Assessment of pH dependence of 14N-QPs.  
As pH controls the physical state of the poly-His solid/liquid status 
and given that the 14N-QPs are only observed for immobilized 
systems [16], changes in the intensity of the imidazole QPs can act 
as a reporter of the pH of the microenvironment. In fact, the 
protonation of the imidazole group of the histidine (pKa=6.8)[23,24] 
increases the polymer solubility with a consequent increase in 
mobility and progressive disappearance of the QPs (Figure 2E). 
 
Poly-Histidine containing nanoparticles. 
As the appearance of the 14N-QPs is associated with an 
immobilized physical state of the moiety generating the proton 
relaxation enhancement of the surrounding water molecules, 
nano- or micro-particles represent a suitable form for the new 
class of contrast agent. We have pursued the task of generating 
nanoparticle-based contrast agents by confining the poly-His 
chains responsible for the 14N-QPs inside a biocompatible 
nanoparticle. In fact, the overall dynamics of the imidazole-
containing chain has an important role in the generation of the 
14N-QPs and the immobilization of the polymeric chains in a 
tissue-like state is mandatory. Accordingly, an oligopeptide 
containing 15 histidines was conjugated to polylactic and glycolic 
acid (PLGA) co-polymers to yield hybrid nanoparticles (Figure 3 
and Supplementary Materials, Figure S2-S6). PLGA is approved 
by the US Food and Drug Administration (FDA) and the European 
Medicine Agency (EMA) in several drug delivery systems for 
human use [25,26]. These polymers are commercially available at 
different molecular weights and copolymer compositions. 
Furthermore, the interior of PLGA nanoparticles (PLGA-NPs) is 
accessible to bulk water to an extent that is inversely proportional 
to the size of the NP [27,28]. In order to allow the incorporation of 
many histidine units into the PLGA-NP, an oligo-His peptide 
(amino acid sequence: CGGHnA, n=15) was synthesized by 
Solid Phase Peptide Synthesis (SPPS) using the Fmoc strategy. 
The  NMRD profile of the oligo-His peptide suspension was not 
significantly different from that obtained from the commercial 
polyaminoacid sample (ca. 114 residues, see Supplementary 
Materials, figure S7).  
Then, the oligo-His peptide was conjugated to the PLGA-PEG2-
maleimide derivative, through the coupling between the N-
terminal cysteine residue (C) and the maleimide terminal groups 
of PEG, following the procedure as described in figure 3. The 
chemical structure of the final product oligo-His-PLGA was 
confirmed by 1H-NMR spectra (see Supplementary Materials, 
figure S6). The PLGA-NPs were obtained by applying the 
oil/water (o/w) emulsion solvent extraction method.[27] The organic 
phase was prepared by dissolving the oligo-His-PLGA and the 
PLGA Resomer® RG 502 H (1:1) in chloroform:methanol (75:25). 
The water phase was a PolyVinyl Alcohol (PVA) aqueous solution 
(3%). PVA is the most commonly-used emulsifier for the 
preparation of PLGA-NPs because it yields particles that are 
relatively uniform, small sized, and which can be easily re-
dispersed in water.[29] The average hydrodynamic diameters of 
the oligo-His-PLGA-NPs were determined by dynamic light 
scattering (DLS) measurements, and were equal to ca. 150 nm 
(157 ± 2 nm). The NMRD profile acquired on suspensions 
containing oligo-His-PLGA-NPs (at a 5 mg/ml oligo-His 
concentration) is reported in Figure 4. It showed that the imidazole 
QP is more pronounced (R1=0.20 s-1, +67%) than the 
corresponding one obtained for the commercial poly-His at the 
same concentration (R1 = 0.12 s-1). Profiles acquired in the pH 
range 5.5-7.4 showed the same pH dependence of Oligo-His-
PLGA QPs intensity observed with poly-His (Figure 2E), with a 
slight shift toward more acid pHs (Figure S8).   
 
In vivo 14N-QPs detection of oligo-His-PLGA-NPs in murine 
tumour xenograft.  
In order to test whether the QP generated by poly-histidine based 
contrast agents could be detected in vivo in tumour animal models, 
the NMRD profiles were acquired using a prototype FFC 
relaxometer endowed with a wide-bore magnet, sufficient to 
accommodate mice of 20-25 g [30]. Due to the absence of spatial 
resolution, in order to excite a small, well-defined volume 
containing the tumour region, a surface microcoil of elliptical 
shape defined by 3 and 2 mm axes (Area = 4.71 mm2) was used. 
The penetration depth of the coil is about 1.5 mm (Figure 5A). For 
this purpose 1 million of murine breast cancer cells (4T1) were 
injected intramuscularly, in the mouse leg, 10 days before the 
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were injected directly into the tumour at a dose of 0.1 mmol/kg 
calculated on the base of the mmol of the oligo-His-PLGA polymer 
(MW=15300) administrated to the animal. Figure 5B shows that 
the relaxation rate increment measured at ca 1.33MHz was 
readily detectable, with R1 of 1.7 s-1, corresponding to a 42.5% 
increase with respect to the relaxation rate measured at 1.65 MHz.  
 
Figure 3. Synthesis scheme of oligo-His-PLGA. Schematic representation of the synthesis steps to obtain oligo-His-PLGA. 
 
 
Figure 4. The oligo-His-PLGA-NP. (A) NMRD profiles of oligo-His-PLGA-NP 
(◊) in comparison to the commercial poly-His (●), at the same [His], i.e  5 mg/ml. 
(B) Expansion of the QP region. (C) Schematic representation of an oligo-His-
PLGA NP. It was prepared according to the oil/water (o/w) emulsion solvent 
extraction method with PVA coating. See text for more details. Abbreviations: 
PLGA= Poly (Lactic-co-Glycolic Acid)-PEG2-Mal chain; PVA = PolyVinyl 
Alcohol. 
 
On the contrary, the increase measured before the contrast agent 
injection at the same frequencies was not significantly different 
from zero. Due to the lower sensitivity of the surface coil, in order  
Figure 5. In vivo experiment with the oligo-His-PLGA NPs. (A) The mouse 
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relaxometer. The arrow indicates the surface coil (from Voxalytic). (B) The 
relaxation rate differences acquired at 1.33 and 1.6 MHz PRE and POST the 
oligo-His-PLGA injection. The PRE data were acquired using two different coils, 
see text.  
 
to obtain a sufficient signal-to-noise ratio it was necessary to 
average 4 scans, causing a marked increase of the 
acquisitiontime. These preliminary results demonstrate that the 
relaxation rate increase caused by this new polymeric (oligo-His-
PLGA) contrast agent was readily detectable also after its “in vivo” 
injection.   
 
Imaging of poly-Histidine nanoparticles by FFC Imager 
The contrast generating ability of poly-His nanoparticles was 
assessed using a whole-body FFC MRI scanner. NMRD profiles 
obtained from whole sample non-imaging experiments are shown 
in Figure 6A. The NMRD profile obtained from oligo-His NPs show 
exogenous and endogenous QPs consistent with the relaxometry 
data. A contrast image was produced from the height of the QP 
(R1) at 33 mT (Figure 6B). The oligo-His NPs showed evident 
quadrupolar-induced relaxation differences compared to the 
blank nanoparticles. Region-of-interest analysis[31] of the contrast 
image (Figure 6C) yielded a greater positive image contrast 
(median (QR) R1 of 0.095 (0.092 – 0.099) s-1) from ologo-His 
nanoparticles compared to that obtained from the blank 
nanoparticles (R1 of 0.023 (0.021 – 0.033) s-1).  
 
Figure 6. Imaging of Oligo-His NPs by FFC MRI. (A) NMR dispersion from 
single sample non-imaging experiment. Sample containing oligo-His NPs is 
shown in black. Sample containing nanoparticles without oligo-His (Blank NP) 
is shown in blue. Error bars represent the 95 % confidence interval obtained 
from each fit. (B) R1 image contrast obtained from the quadrupolar peak height 
at 33 mT with an in plane resolution of 2.19 x 2.19 mm. (C) Dot plot of the voxel 
R1 for each sample. Each dot represents a single value with each region-of-
interest. The median and IQR value is indicated for each sample.  
 
Discussion 
The ability to measure water proton T1 values over an extended 
range of magnetic field strengths introduces an entirely new 
dimension into biomedical NMR and MRI. By carrying out 
measurements as a function of magnetic field strength, 
completely new routes for obtaining contrast between normal and 
diseased tissues can be explored. The present study was 
designed to develop an innovative class of MRI contrast agents 
based on the generation of detectable 14N-QPs that fall at 
frequencies that are readily distinguishable from those associated 
with the amidic peptide functionalities of endogenous tissue 
proteins whose 14N-QPs fall at 0.7, 2.1 and 2.8 MHz, respectively. 
The observation of 14N-QPs is strictly dependent on the 
immobilization in a gel state of the polymers containing the 
imidazolic moieties. In fact, 14N-QPs are not seen in the case of 
isotropically-tumbling proteins or polymers, but their appearance 
requires that the molecular dynamics have to be slowed down on 
the time scale of the inverse quadrupole coupling constant (i.e. < 
50 ns)[18]. Moreover, 14N-1H coupling concerns not only hydrogen 
atoms directly bound to nitrogen but also protons of the hydration 
water layer (about 55% of the exchangeable hydrogen nuclei that 
directly or indirectly sense the coupling interaction). Therefore, 
the water molecules forming the intermediate layer also have to 
be in a kind of slow-motion regime for them to transfer the 14N-1H 
relaxation to the “bulk” water. On this basis, the herein-considered 
imidazole-containing polymers were conjugated to biocompatible 
polymers such as polylactic and glycolic acid (PLGA), in order to 
form stable nanoparticles containing structured water in their 
inner cavities. Once administered in vivo these nanosized 
particles are expected to act as vascular and extra-vascular 
agents (in the presence of fenestrated capillaries), in analogy to 
what is observed for other NPs such as those based on iron 
oxides [32] or those based on PLGA containing GBCAs [33,34]. In 
addition, the 14N-QPs of histidine-containing peptides may act as 
pH sensors, in turn providing valuable information on tumour cell 
metabolism. The measurement of tumour tissue pH has a marked 
prognostic relevance as the presence of slightly acidic zones (e.g. 
pH=6.6-6.8) surrounding hypoxic and necrotic areas is known to 
be an important factor in promoting cell migration and metastasis. 
Furthermore, an increase in poly-His mobility due to the pH 
decrease associated with cell death may also be detected in the 
case when the imidazole units are part of a scaffold matrix. In 
principle, one may envisage several conditions in which the 
overall dynamics of the imidazole-containing polymers could act 
as reporters of local physiological and pathological changes. The 
immobilization of the polymeric chains in a tissue-like state is 
mandatory for the generation of the 14N-QPs and, since pH 
controls the physical state of the poly-His solid/liquid status, an 
estimate of the pH of the microenvironment in which the poly-His 
polymer is located can be acquired by the changes in the intensity 
of the imidazole QP.  
The intensity of poly-His QPs is pH-dependent and its observation 
is possible only when poly-His is at pH > 6.6. This occurs because 
the transfer of the quadrupolar 14N relaxation to the bulk water, 
which drives the bulk relaxation and produces the QPs, is only 
possible when water molecules are present in the hydration 
sphere of immobilised Poly-His polypeptide (with a tumbling time 
of the order of tens of nanoseconds) [16]. In this context, PLGA 
appear to be good candidates because of their ability to form rigid 
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detectable when oligo-His moieties are embedded in the 
nanoparticles. In principle, PLGA can be replaced by other 
biocompatible polymers as the generation of the 14N-QP at 1.38 
MHz seems to be independent of the chemical compounds that 
constitute the semi-solid matrix in which the poly-His moiety is 
embedded.  
The idea of developing MRI contrast agents based on the 
detection of QPs has also been recently tackled by Scharfetter et 
al.[35–37]. They investigated 209Bi (I=9/2) containing organometallic 
compounds reporting interesting results that, however, appeared 
difficult to translate into living systems. Conversely, the poly-His 
containing compounds herein proposed are metal-free and highly 
biocompatible, biodegradable and non-toxic. 
Conclusions 
Access to the relaxation enhancement provided by the 14N-QPs 
appears to offer a very promising approach to generate contrast 
in MR images. Imidazole showed itself to be a good candidate as 
it yields a 14N-QP readily detectable from the naturally occurring 
ones, due to the amide functionalities of the semi-solid proteins. 
Contrary to the currently used GBCAs, this new class of agent is 
not represented by water-soluble molecules but rather has to be 
part of a solid system that restricts mobility. The physical form 
may range from water-suspended nanoparticles (as shown in this 
report) to bulkier devices such as cell-hosting scaffolds. The pH-
responsiveness of the 14N-QP generated by imidazole moieties 
appears to be an important property that allows the design of 
systems able to sense the local pH, which can then act as 
reporters of pathological conditions that are known to affect the 
local pH. As the effect of imidazole 14N-QP is detected at 1.38 
MHz, this implies that it cannot be observed on current clinical 
MRI scanners. Fast Field Cycling imagers are needed for its 
exploitation and one may expect that the results reported here 
may be useful for further accelerating the development of the next 
generation of instruments based on the acquisition of MR images 
over an extended range of magnetic fields.[19]  
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Insert text for Table of Contents here. In this study, we developed completely new, metal free, MRI contrast agents  that differ completely 
from current clinical contrast agents, which contain potentially toxic paramagnetic metals. These sensors enhance image contrast 
thanks to the 14N of imidazole groups of histidine, which are conjugated to the PLGA polymeric chains forming pH-sensitive, 
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